EZR and neoplasm: Another study in 2019 suggested the co-localization of CA9 with phosphorylated ezrin (EZR), activated the hypoxia–autophagy–EZR pathway in tumor-initiating human cells and primary CRC tissues, proving its clinical relevance [85].